Experimental mitochondrial uncoupler · Fact sheet

BAM15

BAM15 is a research mitochondrial uncoupler investigated in cell and animal models. Preclinical metabolic findings do not establish a safe human fat-loss dose or an alternative to exercise.

Preclinical researchMostly animal or lab research

What is BAM15?

Mitochondrial uncoupling reduces the coupling between nutrient oxidation and ATP production. Altering this process can change energy expenditure.

BAM15 is a small molecule, not a peptide, and specialized nanoparticle formulations are different from unformulated material.

Benefits & claims

Interest centers on metabolism, body composition and cellular energy. A favorable animal comparison with older uncouplers does not establish human safety.

What the evidence supports

  • A liver-targeted albumin nanocomposite study reported metabolic effects in experimental models.
  • A leukemia study found cellular oxidative effects and activity in mice.
  • A nematode lifespan result does not demonstrate longer human life or safe human uncoupling.
Research areas
  • Preclinical metabolic disease
  • Mitochondrial uncoupling
  • Experimental cancer biology

Dosage & frequency

No established human regimen

The reviewed sources do not establish a human treatment amount or frequency for BAM15. Animal and laboratory exposures are not human regimens.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Identity and pharmacology
Mitochondrial uncoupling reduces the coupling between nutrient oxidation and ATP production. Altering this process can change energy expenditure.

Formulation differences

  • BAM15 is a small molecule, not a peptide, and specialized nanoparticle formulations are different from unformulated material.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Human pharmacokinetics and adverse effects
  • Separation of metabolic effects from toxicity
  • Long-term tissue consequences

Side effects & risks

  • Human therapeutic margin, temperature effects, cardiovascular consequences and organ toxicity remain unestablished.
  • Delivery systems can change exposure; claims for a nanoparticle product cannot certify safety of raw BAM15.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

Animal and cell studies explore metabolic and cancer-related effects. Species, formulation and experimental-disease differences limit translation.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

No attributable personal accounts were found in the sources reviewed.

Approval status

BAM15 has no FDA-approved therapeutic product. The cited studies involve cells, mice or nematodes, not an established human dosing program.

Preclinical evidence; no FDA-approved product

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Human pharmacokinetics and adverse effects
  • Separation of metabolic effects from toxicity
  • Long-term tissue consequences

Summary

A nematode lifespan result does not demonstrate longer human life or safe human uncoupling.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedBAM15 albumin nanocomposites

    Preclinical liver-targeted formulation study.

  2. pubmedBAM15 in leukemia models

    Cell and mouse research on oxidative stress and apoptosis.

  3. pubmedBAM15 in aging nematodes

    Worm neuronal and lifespan experiments.

How we assess sources · Suggest a correction